United States · Bill · S
S. 150 (118th)
Affordable Prescriptions for Patients Act of 2023
Introduced
30 January 2023
Last action
15 July 2024 · Floor
Status
Held at the desk.
Sponsors
Sen. Cornyn, John [R-TX], Sen. Blumenthal, Richard [D-CT], Sen. Grassley, Chuck [R-IA], Sen. Durbin, Richard J. [D-IL], Sen. Cruz, Ted [R-TX], Sen. Klobuchar, Amy [D-MN], Sen. Braun, Mike [R-IN], Sen. Welch, Peter [D-VT], Sen. Murkowski, Lisa [R-AK]
Subjects
Healthcare
Source updated
10 August 2026
Summary
Affordable Prescriptions for Patients Act of 2023 This bill prohibits product hopping by drug manufacturers, authorizes the Federal Trade Commission to enforce this prohibition, and imposes limits on patent litigation involving biological products. Generally, product-hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantially similar to an indication of the reference drug. The bill presumes product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration (FDA) has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product. A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition. The bill also limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get FDA market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
30 January 2023
Introduced
Read twice and referred to the Committee on the Judiciary.
Source: IntroReferral
30 January 2023
Introduced
Introduced in Senate
Source: IntroReferral
9 February 2023
Reported
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Source: Committee
1 March 2023
Calendars
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Source: Calendars
1 March 2023
Reported
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Source: Committee
1 March 2023
Reported
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Source: Committee
11 July 2024
Floor
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Source: Floor
11 July 2024
Passed
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Source: Floor
12 July 2024
Floor
Message on Senate action sent to the House.
Source: Floor
15 July 2024
Floor
Held at the desk.
Source: Floor
15 July 2024
Floor
Received in the House.
Source: Floor
Votes
No vote records are attached yet.
Versions
- Engrossed in Senate · 11 July 2024 · Download file
- Reported to Senate · 1 March 2023 · Download file
- Introduced in Senate · 30 January 2023 · Download file
Documents
9 official files
Engrossed in Senate (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Engrossed in Senate (text)
Engrossed in Senate · EN · 11 July 2024
Engrossed in Senate (PDF)
Engrossed in Senate · EN · 11 July 2024
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Passed Senate
summary · EN · 11 July 2024
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Reported to Senate (text)
Reported to Senate · EN · 1 March 2023
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Reported to Senate (PDF)
Reported to Senate · EN · 1 March 2023
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Reported to Senate
summary · EN · 1 March 2023
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in Senate (text)
Introduced in Senate · EN · 30 January 2023
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in Senate (PDF)
Introduced in Senate · EN · 30 January 2023
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in Senate
summary · EN · 30 January 2023
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Sen. Cornyn, John [R-TX] · R · Sponsor
- Sen. Blumenthal, Richard [D-CT] · D · Sponsor
- Sen. Grassley, Chuck [R-IA] · R · Sponsor
- Sen. Durbin, Richard J. [D-IL] · D · Sponsor
- Sen. Cruz, Ted [R-TX] · R · Sponsor
- Sen. Klobuchar, Amy [D-MN] · D · Sponsor
- Sen. Braun, Mike [R-IN] · R · Cosponsor
- Sen. Welch, Peter [D-VT] · D · Cosponsor
- Sen. Murkowski, Lisa [R-AK] · R · Cosponsor
- · ssju00 · Standing
Related records
- related to ← Affordable Prescriptions for Patients Act of 2024
- related to ← Affordable Prescriptions for Patients Act of 2021
- amends ← In the nature of a substitute.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/senate-bill/150
- Open data entity: https://api.congress.gov/v3/bill/118/s/150
- us · 118-s-150 · source updated 10 August 2026